

HEALTH PROMOTION BUREAU

Chronic Disease Surveillance Report



Montana Asthma Control Program

1400 E Broadway Helena, Montana 59260-2951 (406) 444-7304

http://www.dphhs.mt.gov/asthma



Asthma Medication Use and Treatment Guidelines

Varied use of asthma medications

A variety of medications are used to reduce and control asthma symptoms. For people with persistent asthma symptoms, two classes of medications are required for proper treatment: rescue and controller medications. The Expert Panel Review (EPR-3) Guidelines¹ recommend that

a long-term controller medication such as an inhaled corticosteroid (ICS) be taken daily to achieve and maintain control of persistent asthma. The EPR-3 also recommends that Short-Acting Beta₂-Agonists (SABA) be used in response to symptoms.

ONE-THIRD OF ADULTS
AND CHILDREN WITH
CURRENT ASTHMA
REPORTED NOT HAVING
ANY ASTHMA MEDICATIONS.

OF THOSE WITH MEDICATIONS, 40% DID NOT USE THE MEDICATION PROPERLY.

However, the use of a SABA (rescue inhaler) more than 2 days per week (excluding for prevention of exercise induced asthma) indicates inadequate control of asthma. The EPR-3 also recommends the use of oral systemic corticosteroids (OCS) for moderate to severe exacerbations. However, if an individual requires more than one course of OCS in a year, it indicates that the person's asthma is not in control. The following report describes medication use among Montanans with current asthma based on self-reported data from the Asthma Call-Back Survey.

Reported Use of Asthma Medications

■ Adults ■ Children

Rescue Only

All people with asthma should have a rescue medication. Those with persistent asthma symptoms should have both rescue and controller medications. Among adults and children in Montana with current asthma, only 55% and 57%, respectively, reported having a rescue medication (Figure 1). Thirty-seven percent of adults and 43% of children with current asthma reported using a controller medication (Figure 1). Of adults and children on a controller medication, the majority (77%) reported using an ICS. Other common controller medications were inhaled long-acting beta agonists (LABA) (60%), and leukotriene modifiers (39%). Of people reporting use of a rescue asthma medication the most common medication was an

inhaled SABA (94%). Finally, very few adults and children reported having used an OCS in the last 3 months (data not shown).

Approximately one-third of adults and children with current asthma reported not having any prescription medication to treat their asthma (Figure 1). Without the ability to self-manage asthma symptoms, an exacerbation may lead to an unnecessary emergency department visit or hospital admission.

Control and


Rescue

Proper Use

No Prescription

Figure 2. Percent of adults and children with current asthma who used their asthma medications properly, ACBS², Montana, 2006-2010

Control Only



Proper use of medication is important for establishing and maintaining asthma control. For control medication, proper use means taking it on a daily basis, but not taking it during an attack or before exercising. For rescue medication, proper use means taking it during an attack and not taking it on a daily schedule. Approximately 60% of adults and children reported proper use of their inhaled control and rescue medications (Figure 2).

LABAs should only be used in conjunction with an ICS. Nearly all adults (94%) and all children (100%) with current asthma who took a LABA in the last 3 months also reported taking an ICS (data not shown).

How to determine medication use

The Montana Asthma Call-back Survey (ACBS) is a telephone survey of non-institutionalized adults aged 18 and over. Participants are recruited from the Behavioral Risk Factor Surveillance System (BRFSS) survey if they indicate that they either had or currently have asthma. During the BRFSS, a child is also randomly selected from the household and the parent or guardian responds to a selection of questions on their behalf. Individuals who self-report that they have asthma (or their parent or guardian) are then called again and asked more indepth questions about their experience with asthma and their use of

depth questions about their experience with asthma and their use of specific asthma medications. Montana has participated in the ACBS, funded by the Centers for Disease Control and Prevention, annually since 2006.

Spacers are aerosol-holding chambers that can help deliver asthma medication to the lungs more efficiently. This can lead to improved response and reduced cost due to wasted medication. Adults and children reported using a spacer with an inhaled SABA or an ICS 32% and 44% of the time, respectively (Figure 3). Proper inhaler technique can help better deliver asthma medication as well. One in five adults and children with asthma reported they had never had a health professional watch them use their inhaler (Figure 3).





Figure 4. Summary of stepwise approach to asthma medications



Chronic Disease Prevention and Health Promotion

BUREAU

1400 E Broadway Helena, MT 59620-2951

For more information contact:

Katie Loveland
Program Manager
(406) 444-7304
kloveland@mt.gov

Clinical Recommendations

- Ensure each asthma patient has at minimum a rescue inhaler
- Recall asthma patients for semi-annual visits to discuss asthma symptoms, medication adherence, and control
- Use the stepwise approach when prescribing asthma medications
- Teach patients when and how to use asthma medications and observe patients' inhaler technique regularly
- Recommend using a spacer to patients with inhaled medications

Report Highlights: Asthma Medication Use

- Asthma medication use among Montana adults and children
- Self-reported proper use of asthma medications and spacers
- Summary of stepwise approach to asthma medication prescription

3900 copies of this public document were published at an estimated cost of \$0.22 per copy, for a total cost of \$000.00, which includes \$000.00 for printing and \$0.00 for distribution. This publication was supported by the Cooperative Agreement Number CDC-RFA-EH09-901 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.